• 160+

    The UK’s most active investor in UK university spin-outs

  • £500M

    Over £500m raised; invested into over 160 companies

  • £145M

    Cash returned to investors via exits

  • £1.3Bn

    Part of FTSE 250 sector specialist group with £1.3bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Ian Broadhurst
Harriet Doherty
Alun Williams
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Orthox Holdings

Orthox is a medical device company founded in 2008 to exploit FibroFix, a novel silk-based biomaterial platform, for the repair of injuries to cartilage and bone. FibroFix combines exceptional strength and resilience with a porous architecture and chemical structure similar to Fibronectin, an essential component of human cartilage.

Creavo

Creavo has developed diagnostic technology using magnetocardiography (MCG) to measure fluctuations in magnetic fields caused by heart activity. The first product resulting from the work will help physicians in A&E departments rule out significant heart disease in patients presenting with chest pains. This represents a considerable portion of A&E patients but existing protocols take up

QKine

QKine spun-out from the  University of Cambridge in 2016. The company manufactures high quality growth factors and cytokines for stem cell, organoid and regenerative medicine applications. QKine uses proprietary protein purification and engineering technology to make recombinant proteins in E.coli. 

View Portfolio